Stada Moves Closer To Top-3 Target With Strong Showing In 2022
Executive Summary
Stada's Consumer Healthcare business grew faster than the market in 2022, and outpaced many of its peers, taking the company closer to its goal of becoming a top-three European OTC player.
You may also be interested in...
Stada Strikes Deal With Sanofi For Well-Established European Brands
Stada will strengthen its Consumer Healthcare business in key markets like Germany and the UK with the acquisition from Sanofi of an OTC brand portfolio including Opticrom eye drops and Omnivit vitamins.
Stada Strikes Deal With Sanofi For Well-Established European Brands
Stada will strengthen its Consumer Healthcare business in key markets like Germany and the UK with the acquisition from Sanofi of an OTC brand portfolio including Opticrom eye drops and Omnivit vitamins.
Thinking Locally Propelling Stada CHC’s Rapid Growth In Europe
In this exclusive interview, Stada Consumer Healthcare's global head Volker Sydow discusses the company's growth ambitions for the business in Europe and further afield. Sydow outlines Stada CHC's local brand hero strategy, an approach which he says sets the firm apart from the competition.